Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553410 · ClinicalTrials.gov registry record · Phase 3
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
A Phase 3 study, sponsored by ETOP IBCSG Partners Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,884
- Enrollment target
NCT00553410 is a Phase 3 study that has completed, run by ETOP IBCSG Partners Foundation. The registered enrollment target is 4,884 participants.
The verdict
NCT00553410, a Phase 3 study, has completed, sponsored by ETOP IBCSG Partners Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,884 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is more effective in postmenopausal women who have received hormone therapy for early-stage breast cancer. PURPOSE: This randomized phase III trial is comparing two different regimens of letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, early-stage breast cancer.
Interventions
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,884 participants |
| Start Date | 2007-08 |
| Est. Completion | 2019-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553410
The ClinicalTrials.gov registry entry for NCT00553410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,884 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ETOP IBCSG Partners Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letrozole is the first listed.
NCT00553410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00553410 about?
NCT00553410 is a clinical study titled "Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is more effective in postmenopausal women who have received hormone therapy for early-stage breast canc...
What is the current status of trial NCT00553410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,884 participants. The study started on 2007-08. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT00553410?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT00553410?
This trial is sponsored by ETOP IBCSG Partners Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.